Ultragenyx Pharmaceutical Inc. 8-K

What Happened
Ultragenyx Pharmaceutical Inc. (RARE) issued a press release on February 23, 2026, and filed an 8-K announcing that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for DTX401 (pariglasgene brecaparvovec), an AAV gene therapy for Glycogen Storage Disease Type Ia (GSDIa). The FDA granted the BLA Priority Review and set a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026. The company included customary forward-looking statements and risk disclosures in the filing.

Key Details

• Filing date/announcement: February 23, 2026 (8-K / press release).
• Product: DTX401 (pariglasgene brecaparvovec), an AAV gene therapy for GSDIa.
• Regulatory status: FDA accepted the BLA and granted Priority Review.
• PDUFA target action date: August 23, 2026.
• Filing also notes potential future FDA inspections of the company’s gene therapy manufacturing facility and other regulatory interactions; forward-looking risk disclaimers reference the company’s Feb 18, 2026 Form 10-K.

Why It Matters
FDA acceptance and Priority Review accelerate the official review timeline for DTX401 and set a clear regulatory milestone (PDUFA Aug 23, 2026) that investors can watch. A favorable outcome could materially affect Ultragenyx’s clinical-stage pipeline and future revenue potential for a rare-disease gene therapy; conversely, the filing highlights regulatory, manufacturing and development risks that could affect timing and outcomes. The 8-K is primarily an update on regulatory progress rather than clinical results or financials.